Trialbee secures more capital, wants to expand its clinical trial technology business in USA.
Trialbee, a Malmö, Sweden-based company providing a SAAS designed to create holistic digitalization of the patient journey in clinical trials, announced securing additional capital investment in the company. The money comes from existing investors, including Industrifonden, Briban Invest, Birgerson Invest LLC and Ulf Wiinberg Consult & Invest AB,
Anders Tullgren, Daniel Spasic and Newton Aguiar.
As a part of Trialbee’s plans for expansion in the US market, the company has recruited two new executive leadership roles. Lollo Eriksson has been appointed CEO, succeeding founder Tobias Folkesson, who is assuming the role of Strategic Technology Advisor. Robert Molander has joined as the global Senior VP of Marketing.
Eriksson and Molander bring extensive clinical and commercial life science experience to the company. The board has been further strengthened by the addition of Anders Tullgren (as chairman), Newton Aguiar and Daniel Spasic (board members). Tullgren brings pharmaceutical executive leadership experience, Aguiar private equity healthcare experience while Spasic is the founder of the global CROTFS.
Trialbee, founded in 2010 by Tobias Folkesson, developed a cloud-based platform to connect patients, investigators and sponsors and support workflows across the study chain. The company's product suite is designed to create holistic digitalization of the patient journey in clinical trials.
Prior to this, Trialbee raised more than $8M from outside investors.